SVF
Level B· Emerging Clinical EvidenceRandomized Controlled Trial

Cell-Free Fat Extract (CEFFE) as a Versatile Cell-Free Biologic for Multitissue Regeneration: From Skin and Bone to Nerve, Reproductive, and Systemic Applications-A Comprehensive Review.

Karimi Rouzbahani A., Aliakbari M., Amiri B., Fereydoonnezhad T., Behzadi A., Delfani S.

Randomized Controlled Trial on Osteoarthritis, Disc Degeneration, Neuroinflammation, Chronic Wound, published in Biomed Res Int (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Biomed Res Int (2026)
Country
United States
Reported sample size
—
PMID
42543249
DOI
10.1155/bmri/9479492

Abstract (original English)

Cell-free fat extract (CEFFE), an adipose-derived biologic, offers a potent alternative to cell-based therapies by delivering a complex milieu of growth factors (e.g., VEGF, EGF, and BDNF) and regulatory proteins without the tumorigenic, immunogenic, or ethical challenges associated with stem cell applications. The objective of this study is to systematically evaluate CEFFE's regenerative efficacy across diverse tissue systems-including musculoskeletal, neural, reproductive, dermal, ocular, and systemic applications-while synthesizing its underlying molecular mechanisms, clinical outcomes, and translational challenges. A comprehensive literature review was conducted utilizing databases such as PubMed, Scopus, and Web of Science, focusing on preclinical and clinical studies published from January 2018 to May 2026. Over 55 articles were analyzed to evaluate CEFFE's efficacy, dosage-response patterns, and molecular pathways. CEFFE accelerates tissue repair through three conserved mechanistic axes: antiapoptotic survival (e.g., PI3K-Akt/mTOR activation and NRF2-mediated antiferroptosis), context-specific immunomodulation (e.g., Annexin A5-mediated M2 macrophage polarization and NLRP3 inflammasome disruption), and extracellular matrix remodeling alongside angiogenesis (e.g., TGF-β/Smad signaling). Emerging evidence highlights CEFFE's efficacy in novel domains such as intervertebral

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies exist, but sample sizes, methodology, or follow-up remain limited, so conclusions are not firm.

How we grade evidence
HumansAnimalsRegenerationSkinAdipose TissueBone and BonesCell-Free System
Back & SpineSystemic / IVOsteoarthritisDisc DegenerationNeuroinflammationChronic Wound
View on PubMedDOI

Related research